Celeris to Continue Trading On Nasdaq National Market.Business Editors NASHVILLE, Tenn.--(BUSINESS WIRE)--March 8, 2000 Celeris Corporation (Nasdaq/NM:CRSC CRSC Combat-Related Special Compensation (US military) CRSC Center for Research in Scientific Computation CRSC Northern Californian Rabbit Specialty Club CRSC Calibration and Repair Support Company ) today announced that its appeal to Nasdaq to continue being listed on the Nasdaq National Market has been successful. The Company was informed in a letter received from Nasdaq on March 6, that it would continue to be listed on the Nasdaq National Market because the value of the Company's float had exceeded the minimum listing requirement of $5 million for a prescribed number of consecutive trading days In Business, the trading day is the time span that a particular stock exchange is open. For example, the New York Stock Exchange is, as of 2006, open from 09:30AM to 4:00PM. Trading days never take place on weekends. . Based upon the closing price of the Company's stock of $6.32 on March 7, the market value of the Company's public float was approximately $15.3 million. Barbara A. Cannon, president and chief executive officer of Celeris Corporation, said, "We continue to gain traction in building our business, as evidenced by our increasing revenues, decreasing losses, and a solid backlog of new business. We believe the recent increase in our market capitalization Market Capitalization A measure of a public company's size. Market capitalization is the total dollar value of all outstanding shares. It's calculated by multiplying the number of shares times the current market price. This term is often referred to as market cap. is evidence that the market is beginning to recognize our value, Internet initiatives and increasing visibility within our industry." Celeris Corporation is a provider of specialty clinical research and information technology services that expedite ex·pe·dite tr.v. ex·pe·dit·ed, ex·pe·dit·ing, ex·pe·dites 1. To speed up the progress of; accelerate. 2. and streamline the clinical trial and regulatory submission process for pharmaceutical, medical device and biotechnology manufacturers. This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. include statements of intent, belief or current expectations of Celeris Corporation and its management. Such forward-looking statements are not guarantees of future results and involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements. Risks and uncertainties that may cause such differences include, but are not limited to the possibility that the Company may not be able to maintain compliance with Nasdaq National Market continued listing requirements Listing requirements Requirements, including minimum shares outstanding, market value, and income, that are laid down by an exchange for any stock to be listed for trading. , and other risk factors detailed in the Company's Securities and Exchange Commission filings, including the Company's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 1998. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion